新華製藥(000756.SZ)A股異常波動 之前披露2019年度業績快報及全國藥品集採中標
格隆匯2月3日丨新華製藥(000756.SZ)公佈,公司2020年1月23日、2月3日A股股票連續兩個交易日收盤價格漲幅偏離值累計達到20%,根據深圳證券交易所的有關規定,屬於股票交易異常波動的情況。
2020年1月14日公司披露了《2019年度業績快報》,根據公司財務部門初步測算,2019年度,公司實現歸屬於上市公司股東的淨利潤約人民幣3億元,同比增長17.54%。
2020年1月21日公司披露了《關於公司格列美脲片、頭孢拉定膠囊參與全國藥品集中採購中標的公告》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.